EMA Recommendation for the Pediatric Indications of Plerixafor (Mozobil) to Enhance Mobilization of Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Children with Lymphoma or Malignant Solid Tumors.
This article summarizes the scientific review of the application leading to regulatory approval in the European Union. IMPLICATIONS FOR PRACTICE: This review of the marketing authorization of plerixafor will raise awareness of pediatric indication granted for this medicinal product.
PMID: 32154610 [PubMed - as supplied by publisher]
Source: The Oncologist - Category: Cancer & Oncology Authors: Karres D, Ali S, van Hennik PB, Straus S, Josephson F, Thole G, Glerum PJ, Herberts C, Babae N, Herold R, Papadouli I, Pignatti F Tags: Oncologist Source Type: research
More News: Bone Cancers | Brain | Cancer & Oncology | Chemotherapy | Children | Ewing's Sarcoma | Lymphoma | Marketing | Neuroblastoma | Neurology | Neuroscience | Pediatrics | Sarcomas | Stem Cell Therapy | Stem Cells | Study | Transplants